Company profile
UK company 11695725, incorporated on 26 November 2018.
Nanovery
Nanovery Limited is a UK company with status Active founded in 2018 based in North East England.
Company number 11695725
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AA | Transaction MzUzNTUwOTEyN2FkaXF6a2N4
Published 28 Jul 2026 14:54
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 May 2025 to 31 Oct 2026
A rising class of drugs 'Oligonucleotide Therapeutics'(OTs) offer the potential of treatments tailored to specific genetic sequences of patients, alleviating unique genetic disorders and hard-to-treat diseases. The biggest challenge OTs face is delivery to target tissues in sufficient quantities. To overcome this, developers have implemented complex chemi...
1 Oct 2022 to 31 Mar 2024
Chronic diseases are responsible for significant incapacities, suffering, and deaths worldwide and impose a severe economic burden on the nation's health systems. They may be prevented, treated, or even cured if detected on time. While medical imaging and surgical tissue biopsies remain the gold standard in disease diagnostics, these approaches are imprac...
1 Oct 2022 to 30 Sep 2024
Chronic diseases are responsible for significant incapacities, suffering, and deaths worldwide and impose a severe economic burden on the nation's health systems. They may be prevented, treated, or even cured if detected on time. While medical imaging and surgical tissue biopsies remain the gold standard in disease diagnostics, these approaches are imprac...
1 Dec 2021 to 31 Jan 2022
Nanovery is making use of emerging developments in nanorobotics to develop new approaches to diagnosing the world's deadliest diseases, starting with cancer. Early detection together with close tracking of cancer progression and response to treatment greatly improves a patient's experience and chances of recovery. Medical imaging and surgical tissue biops...
1 Apr 2021 to 31 Mar 2022
